Clinical Study of DMT in Healthy Adults
NCT05573568 · Biomind Labs Inc.
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events as clinical and psychiatry symptoms assessed by qualitative medical/clinical-psychiatry evaluation
Measured over up to 1 month after dosing
Blood Pressure
Measured over up to 2 hours after each dose
Heart rate
Measured over up to 2 hours after each dose
Respiratory rate
Measured over up to 2 hours after each dose
Oxygen saturation
Measured over up to 2 hours after each dose
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Hospital Universitário Onofre Lopes | Natal | Rio Grande do Norte | Brazil |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT05573568 on ClinicalTrials.gov →
Last updated in the registry 2023-02-15. Registry records change; this page reflects the data build of 2026-08-25.
Related